SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Revolution Medicines Says Rasonque Improved Survival Across Patient Subgroups

The company said the recently approved pancreatic cancer drug improved overall survival in previously treated patients, regardless of RAS mutation status.

RVMD

Related stories